Hot News: Canadian Solar (NASDAQ:CSIQ), Xplore Technologies (NASDAQ:XPLR), Insteel Industries (NASDAQ:IIIN), Bio-Reference Laboratories Inc. (NASDAQ:BRLI), Sangamo Biosciences Inc. (NASDAQ:SGMO)

On 13 AUG Canadian Solar Inc. (NASDAQ:CSIQ) reported revenues of $623.77 million, a 33.8% year-over-year (YoY) increase, outperformed the Street’s estimate of $577.67, by 8%. The increase in revenues may be attributed to higher shipments to Germany, Japan, the UK, and the US, as well as higher demand from the utility sector in Canada, which led to higher average selling price (ASP). The company’s solar-module … Continue reading Hot News: Canadian Solar (NASDAQ:CSIQ), Xplore Technologies (NASDAQ:XPLR), Insteel Industries (NASDAQ:IIIN), Bio-Reference Laboratories Inc. (NASDAQ:BRLI), Sangamo Biosciences Inc. (NASDAQ:SGMO)

Jayne Crisman08/1808/18

Investors Are Watching – Nokia Corporation (ADR) (NYSE:NOK) , Facebook (NASDAQ:FB) , Sangamo Biosciences (NASDAQ:SGMO) , RPM International (NYSE:RPM) , Bottomline Technologies (NASDAQ:EPAY)

Nokia Corporation (ADR) (NYSE:NOK) is set to release its second-quarter 2014 results before the opening bell on Jul 24, 2014. In the last quarter, the company delivered a positive 50.00% earnings surprise. Likewise, the company has delivered positive earnings surprises in three of the last four quarters, with an average beat of 77.78%. Let’s see how things are shaping up for this announcement. Nokia Corporation … Continue reading Investors Are Watching – Nokia Corporation (ADR) (NYSE:NOK) , Facebook (NASDAQ:FB) , Sangamo Biosciences (NASDAQ:SGMO) , RPM International (NYSE:RPM) , Bottomline Technologies (NASDAQ:EPAY)

Jayne Crisman07/2407/24

Biotech Volatile Stocks: Intrexon Corp (NYSE:XON), Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), Sangamo Biosciences, Inc. (NASDAQ:SGMO), Osiris Therapeutics, Inc. (NASDAQ:OSIR)

Intrexon Corp (NYSE:XON) COO Krish Krishnan purchased 20,900 shares of Intrexon Corp (NYSE:XON) stock in a transaction that occurred on Friday, May 9th. The stock was purchased at an average price of $14.21 per share, for a total transaction of $296,989.00. Following the purchase, the chief operating officer now directly owns 20,900 shares in the company, valued at approximately $296,989. Intrexon Corp (NYSE:XON) stock performance … Continue reading Biotech Volatile Stocks: Intrexon Corp (NYSE:XON), Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), Sangamo Biosciences, Inc. (NASDAQ:SGMO), Osiris Therapeutics, Inc. (NASDAQ:OSIR)

Jayne Crisman05/1505/15

FB Nasdaq FB Facebook

Hot BiotecH Stocks: Alnylam Pharmaceuticals (NASDAQ:ALNY), Sangamo Biosciences (NASDAQ:SGMO), Dyax Corp. (NASDAQ:DYAX), Synthetic Biologics Inc (NYSEMKT:SYN)

It was the biggest loser on the Bloomberg Massachusetts Index: Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), down more than 12 percent. The Cambridge company is developing a new class of medicines based on RNA interference, or RNAi. Alnylam believes that RNAi therapeutics are a promising approach to silence disease-causing genes, according to its website. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stock performance was -12.11% in last session and finished … Continue reading Hot BiotecH Stocks: Alnylam Pharmaceuticals (NASDAQ:ALNY), Sangamo Biosciences (NASDAQ:SGMO), Dyax Corp. (NASDAQ:DYAX), Synthetic Biologics Inc (NYSEMKT:SYN)

Kevin Long04/1104/11

FB Nasdaq FB Facebook

Biotech losers: ZIOPHARM Oncology (NASDAQ:ZIOP), Sangamo Biosciences (NASDAQ:SGMO), Lexicon Pharmaceuticals (NASDAQ:LXRX), XOMA Corp (NASDAQ:XOMA)

On Apr 3, Zacks Investment Research upgraded ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to Zacks Rank #1 (Strong Buy). ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s loss estimates have declining on the back of better-than-expected fourth quarter 2013 results. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) stock performance was -6.06% in last session and finished the day at $4.34. Traded volume was 1.86million shares in the last session and the average volume of … Continue reading Biotech losers: ZIOPHARM Oncology (NASDAQ:ZIOP), Sangamo Biosciences (NASDAQ:SGMO), Lexicon Pharmaceuticals (NASDAQ:LXRX), XOMA Corp (NASDAQ:XOMA)

Colin Pettis04/0404/04

Biotech Volatile Stocks: Incyte Corporation (NASDAQ:INCY), Halozyme Therapeutics (NASDAQ:HALO), Sangamo Biosciences (NASDAQ:SGMO), Nektar Therapeutics (NASDAQ:NKTR)

The only therapy currently approved by the Food and Drug Administration to treat myelofibrosis, a disorder where abnormal blood cells build up inside a patient’s bone marrow, is Incyte (NASDAQ:INCY) and Novartis’ Jakafi (known as Jakavi outside the U.S.), which is a JAK2 inhibitor. JAK2 is an enzyme that plays a key role in signal transduction; therefore, blocking JAK2 can inhibit the development cytokines that … Continue reading Biotech Volatile Stocks: Incyte Corporation (NASDAQ:INCY), Halozyme Therapeutics (NASDAQ:HALO), Sangamo Biosciences (NASDAQ:SGMO), Nektar Therapeutics (NASDAQ:NKTR)

Mark Doerr03/2503/25